189681-04-7

Basic information

• Product Name: 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE
• Synonyms: 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE;4-CHLORO-5-(THIOPHEN-2-YL)THIENO[2,3-D]PYRIMIDINE;BUTTPARK 30\08-40;4-Chloro-5-thien-2-ylthieno[2,3-d]pyrimidine;Thieno[2,3-d]pyrimidine,4-chloro-5-(2-thienyl)-
• CAS NO: 189681-04-7
• Molecular Formula: C10H5ClN2S2
• Molecular Weight: 252.74
• Mol File: 189681-04-7.mol

Chemical Properties

• Melting Point: 110 °C
• Boiling Point: 420.3 °C at 760 mmHg
• Flash Point: 208 °C
• Appearance: /
• Density: 1.52 g/cm³
• Vapor Pressure: 6.95E-07mmHg at 25°C
• Refractive Index: 1.732
• CAS DataBase Reference: 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE(189681-04-7)
• EPA Substance Registry System: 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE(189681-04-7)

Safety Data

• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 189681-04-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 4-CHLORO-5-(2-THIENYL)THIENO[2,3-D]PYRIMIDINE is utilized as a building block for the creation of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness of these products in agricultural applications.

InChI:InChI=1/C10H5ClN2S2/c11-9-8-6(7-2-1-3-14-7)4-15-10(8)13-5-12-9/h1-5H

Upstream product

• 276670-60-1 5′-amino-[2,3′-bithiophene]-4′-carbonitrile 
• 10432-44-7 2-[1-(thiophen-2-yl)ethylidene]malononitrile 
• 88-15-3 2-Acetylthiophene 
• 949526-33-4 5-(thiophene-2-yl)thieno[2,3-d]pyrimidine-4-yl amine 

Relevant articles and documents

Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKβ inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB. However, no inhibitory activity against IKKβ was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML.

Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKβ inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB. However, no inhibitory activity against IKKβ was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML.

NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel thienopyrimidine derivative having an excellent anti? inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. The compound according to the present invention strongly inhibits IKB kinase-β (IKK-β) involved in the activation of a transcriptional factor, NF-κB, which is associated with inducing various immune and inflammatory diseases, whereby a composition comprising the compound is a useful therapeutic agent against inflammatory diseases, in particular, arthritis and cancer.

THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS

The present invention provides thienopyrimidine compounds which are potasium channels inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also provided.